DAVID POPLACK to Injections, Intraventricular
This is a "connection" page, showing publications DAVID POPLACK has written about Injections, Intraventricular.
Connection Strength
0.272
-
Methotrexate distribution within the subarachnoid space after intraventricular and intravenous administration. Cancer Chemother Pharmacol. 2000; 45(3):259-64.
Score: 0.041
-
The Ommaya reservoir: newly recognized complications and recommendations for insertion and use. Cancer. 1978 Jun; 41(6):2431-7.
Score: 0.037
-
Cerebrospinal fluid pharmacokinetics and toxicology of intraventricular and intrathecal arabinosyl-5-azacytosine (fazarabine, NSC 281272) in the nonhuman primate. Invest New Drugs. 1993 May-Aug; 11(2-3):135-40.
Score: 0.026
-
[Infectious complications from intraventricular route of administration in cancer patients]. Probl Med Wieku Rozwoj. 1990; 16:45-53.
Score: 0.021
-
Infectious complications of intraventricular reservoirs in cancer patients. Pediatr Infect Dis J. 1987 Feb; 6(2):182-9.
Score: 0.017
-
Pharmacokinetics of intraventricular and intravenous N,N',N''-triethylenethiophosphoramide (thiotepa) in rhesus monkeys and humans. Cancer Res. 1986 Dec; 46(12 Pt 1):6101-4.
Score: 0.017
-
Prophylaxis and treatment of leukemia in the central nervous system and other sanctuaries. Semin Oncol. 1985 Jun; 12(2):131-48.
Score: 0.015
-
Plasma and cerebrospinal fluid pharmacokinetics of recombinant interferon alpha A in monkeys: comparison of intravenous, intramuscular, and intraventricular delivery. Cancer Drug Deliv. 1985; 2(4):247-53.
Score: 0.015
-
Cytosine arabinoside cerebrospinal fluid kinetics. Clin Pharmacol Ther. 1984 Jun; 35(6):826-30.
Score: 0.014
-
Cerebrospinal fluid pharmacokinetics of intraventricular and intravenous aziridinylbenzoquinone. Cancer Res. 1984 Apr; 44(4):1698-701.
Score: 0.014
-
Intraventricular concentration times time (C x T) methotrexate and cytarabine for patients with recurrent meningeal leukemia and lymphoma. Cancer. 1999 Jan 15; 85(2):511-6.
Score: 0.010
-
Experimental approaches to the treatment of CNS leukemia. Am J Pediatr Hematol Oncol. 1979; 1(2):141-9.
Score: 0.010
-
Intraventricular versus intralumbar methotrexate for central-nervous-system leukemia: prolonged remission with the Ommaya reservoir. Med Pediatr Oncol. 1979; 6(3):207-13.
Score: 0.010
-
A primate model for study of methotrexate pharmacokinetics in the central nervous system. Cancer Res. 1977 Jul; 37(7 Pt 1):1982-5.
Score: 0.009
-
Primate model for long-term study of intraventricularly or intrathecally administered drugs and intracranial pressure. Science. 1977 Feb 04; 195(4277):499-501.
Score: 0.008
-
Active clearance of corticotropin-releasing factor from the cerebrospinal fluid. Neuroendocrinology. 1985 Jan; 40(1):84-7.
Score: 0.004
-
Active transport of methotrexate from cerebrospinal fluid in humans. Cancer Res. 1980 Jul; 40(7):2184-7.
Score: 0.003
-
Chronic ventricular cerebrospinal fluid sampling, drug injections, and pressure monitoring using subcutaneous reservoirs in monkeys. Neurosurgery. 1977 Sep-Oct; 1(2):132-5.
Score: 0.002
-
Reversible dementia temporally associated with intraventricular therapy with methotrexate in a child with acute myelogenous leukemia. J Pediatr. 1976 Jan; 88(1):131-3.
Score: 0.002